Atrial Fibrillation Study Brisbane WH 7003
Atrial Fibrillation Study
Wellers Hill Brisbane
Momentum is conducting a clinical trial evaluating the effectiveness of a new blood thinner treatment intended to stop the formation of blood clots in people with atrial fibrillation, with a significantly reduced risk of bleeding.
Description
What to expect
Ages
18+ years old
Duration
A minimum duration of 3 months, with an expected duration of 2 years.
Compensation
Eligible participants will be compensated for time and travel-related costs.
Eligibility Criteria
You may be eligible to take part if you:
Locations
Blood thinners remain a cornerstone in the treatment for Atrial Fibrillation.
Atrial fibrillation (also knowns as AFib), is a common type of cardiac arrhythmia, which refers to an irregular heartbeat rhythm. As a result, the heart cannot pump blood effectively which can lead to a variety of symptoms, including palpitations, shortness of breath, and fatigue.
Without management, Atrial Fibrillation can lead to formation of blood clots, increasing the risk of stroke, heart failure, and other heart-related complications. Many blood-thinner therapies are currently available, but the disadvantage is that they can increase the risk of bleeding.
Momentum is conducting a study evaluating the effectiveness of a new blood thinner treatment intended to stop the formation of blood clots in people with atrial fibrillation, with a significantly reduced risk of bleeding.
The study has a minimum duration of 3 months, with an expected duration of 2 years.
Eligible participants will be compensated for time and travel-related costs.
Apply now
Fill out your details, and our team will be in touch to discuss your potential involvement in this study and answer any questions you may have.
*You can unsubscribe or opt out at any time.